The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis
Open accessAbstract
Multiple Sclerosis (MS) is a major cause of neurological disability, which increases predominantly during disease progression as a result of cortical and grey matter structures involvement. The gradual accumulation of disability characteristic of the disease seems to also result from a different set of mechanisms, including in particular immune reactions confined to the Central Nervous System such as: (a) B-cell dysregulation, (b) CD8+ T cells causing demyelination or axonal/neuronal damage, and (c) microglial cell activation associated with neuritic transection found in cortical demyelinating lesions. Other potential drivers of neurodegeneration are generation of oxygen and nitrogen reactive species, and mitochondrial damage, inducing impaired energy production, and intra-axonal accumulation of Ca2+, which in turn activates a variety of catabolic enzymes ultimately leading to progressive proteolytic degradation of cytoskeleton proteins. Loss of axon energy provided by oligodendrocytes determines further axonal degeneration and neuronal loss. Clearly, these different mechanisms are not mutually exclusive and could act in combination. Given the multifactorial pathophysiology of progressive MS, many potential therapeutic targets could be investigated in the future. This remains however, an objective that has yet to be undertaken.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neurological deficits in MS patients result from two pathogenic events: acute inflammatory demyelination and axonal injury [150,151].”
From Beneficial Effects of Spirulina Consumption on Brain Health (2022) · cites this paper as [151]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
New Multiple Sclerosis Phenotypic Classification
LUBLIN, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,277
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Chondroitinase ABC promotes functional recovery after spinal cord injury
Bradbury, E. J., Moon, L. D. F., Popat, R. J., King, V. R., Bennett, G. S., Patel, P. N., Fawcett, J. W., & McMahon, S. B. (2002) · Nature · doi:10.1038/416636a · Cited by 2,357
Brain energy metabolism: focus on Astrocyte-neuron metabolic cooperation
Bélanger, M., Allaman, I., & Magistretti, P. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.016 · Cited by 2,313
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Thompson, A. J., Baranzini, S. E., Geurts, J. J. G., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,979
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Oligodendroglia metabolically support axons and contribute to neurodegeneration
Lee, Y., Morrison, B. M., Li, Y., Lengacher, S., Farah, M. H., Hoffman, P. N., Liu, Y., Tsingalia, A., Jin, L., Zhang, P.-W., et al. (2012) · Nature · doi:10.1038/nature11314 · Cited by 1,664 · cited 1×
“Notably, both genetic and pharmacologic down-regulation of MCT1, which is present almost exclusively in oligodendrocytes, results in axon degeneration and neuronal loss both in vivo and in vitro, without obvious oligodendrocyte damage [165].”
Background
Cited by
Sorted by citations
Items 101–166 of 166
Alameri, M. A., Mansour, M., Al-Habahbeh, S., Weshah, F., Ennab, W., & Gammoh, O. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.106206 · Cited by 4
Hoelz, A. G., Bernardes, D., Cartarozzi, L. P., & de Oliveira, A. L. R. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.921916 · Cited by 4
Role of Gut Microbiota in Neuroinflammation and Neurological Disorders
Raj, K., Arora, N., Rohit, B. S. P., Awasthi, A., Patel, M., Chaudhary, A., Singh, S., & Gupta, G. D. (2024) · Frontiers in clinical drug research. CNS and neurological disorders · doi:10.2174/9789815179842124120005 · Cited by 5
Essel, R. R., Krieger, B., Bellenberg, B., Müller, D., Ladopoulos, T., Gold, R., Schneider, R., & Lukas, C. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1537465 · Cited by 5
Mohammadi, S., Mohammadi, M., & Ghaderi, S. (2023) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2023.111727 · Cited by 4
Xie, J., Wu, M., Li, L., Hu, L., Hu, L., Li, W., & Li, W. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151790 · Cited by 6
Ran, Y., Niu, X., Wang, Y., Xu, W., Liang, J., Xu, Y., Chen, S., & Yu, M. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202404742 · Cited by 3
Comparative information of different animal models used in chronic diseases
Goel, F., Giri, A., Kumar, D., Pal, A., & Singh, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33877-9.00014-8 · Cited by 3
Damato, M., Garofalo, N., Schipa, L., Musarò, D., Anzilli, A., Corbo, F., Quarta, A. L., Maffia, M., & Ragusa, A. (2026) · Antioxidants · doi:10.3390/antiox15020172 · Cited by 4
Craner, M. J., Malik, Y. M. A., Babtain, F. A., Alshamrani, F., Alkhawajah, M. M., Alfugham, N. B., Al-Yafeai, R. H., Aljarallah, S., Makkawi, S., Qureshi, S., et al. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00401-4 · Cited by 3
Khalili, M. D., Makvand-Hosseini, S., & Sabahi, P. (2023) · Jundishapur Journal of Chronic Disease Care · doi:10.5812/jjcdc-132672 · Cited by 2
Microstructural Changes in the Corpus Callosum in Neurodegenerative Diseases
Albadawi, E. A. (2024) · Cureus · doi:10.7759/cureus.67378 · Cited by 3
Thrue, C., Hvid, L. G., Diechmann, M., Gaemelke, T., Stenager, E., Dalgas, U., & Riemenschneider, M. (2025) · Neurorehabilitation and neural repair · doi:10.1177/15459683251318246 · Cited by 3
Optical coherence tomography in multiple sclerosis
Krajnc, N., & Bsteh, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95739-7.00008-3 · Cited by 3
Enlarging and shrinking focal perivascular spaces
Boutet, A., Son, H. J., Malik, M., Haile, S. S., Yang, A. Z., Pai, V., Germann, J., & Mandell, D. M. (2024) · The Neuroradiology Journal · doi:10.1177/19714009241242642 · Cited by 2
de Almeida, M. M. A., Kornfeld, S. F., Repentigny, Y. D., Al-Aarg, M., Ghani, I., Cummings, S. E., Sutton, E. R., Yaworski, R., McKay, K. S., Gagnon, S., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106999 · Cited by 2
Immunopathophysiologic basis of multiple sclerosis and implications for therapy-a narrative review
Redfern, J. S. (2021) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2021.09.00355 · Cited by 2
Inflammation and neurodegeneration in multiple sclerosis
Mendes, O. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95735-9.00023-1 · Cited by 2
McBenedict, B., Hauwanga, W. N., Pogodina, A., Devan, J. N., Goh, K. S., Yau, R. C. C., Alphonse, B., ADOLPHSSON, L. I. E., & PESSOA, B. L. (2025) · Sclerosis · doi:10.3390/sclerosis3010002 · Cited by 2
Spirulina: Morphology, Cultivation, Harvesting as a Supplement and Its Therapeutic Properties
Khushala, A., Bobby, M. N., & Balasubramaniyan, M. (2025) · Springer eBooks · doi:10.1007/978-981-96-1844-6_9 · Cited by 2
Sadovnichuk, E. A., Topuzova, M. P., Алексеевна, М. В., Shcherbakova, O. A., & Бисага, Г. Н. (2023) · Российский нейрохирургический журнал им профессора А Л Поленова · doi:10.56618/2071-2693_2023_15_3_158 · Cited by 2
[Pathological and protective effects of tumor necrosis factor-alpha in multiple sclerosis].
Smagina, I., Elchaninova, S. A., Palashchenko, A. S., & Galaktionova, L. P. (2019) · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · doi:10.17116/jnevro20191191014 · Cited by 6
Incidence of Pediatric Multiple Sclerosis in Iran within 2000-2019.
Nasehi, M. M., Nikkhah, A., Moosazadeh, M., Saket, S., & Alizadeh‐Navaei, R. (2022) · Iranian journal of child neurology. · doi:10.22037/ijcn.v16i1.35572 · Cited by 2
Rahamathulla, M., Kumar, R., Alrashdan, Y., Bose, M. M., Muthukumar, A., Salahuddin, M., Ahmed, M. M., Shivanandappa, T. B., & Pasha, I. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04934-1 · Cited by 2
Language in multiple sclerosis
Nordio, S., Zampieri, M., Bambini, V., & Arcara, G. (2025) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780198888482.013.0015 · Cited by 1
Digging deeper into NINJ1: its multifaceted role in central nervous system diseases
Tian, M., Zhou, M., Li, S., & Qu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1838013 · Cited by 1
Kumar, N., Mir, P. A., Bhutia, G. T., Chaudhary, P., Kaur, G., Alam, Q., Pawar, S. D., & Gupta, S. K. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05983-w · Cited by 1
Алексеевна, М. В., Sadovnichuk, E. A., Лепехина, А. С., Бисага, Г. Н., Topuzova, M. P., Shchukina, T. V., Dryagina, N. V., Efimcev, A. Y., & Alekseeva, T. M. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202412407266 · Cited by 1
The next frontier in multiple sclerosis therapies: Current advances and evolving targets
Koduru, T. S., Gupta, N., Kannan, A., Dutta, S., Osmani, R. A. M., Balamuralidhara, V., Ramkishan, A., & Shanmuganathan, S. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177080 · Cited by 1
Pashapouryeganeh, A., Khatrawi, E. M., Pajohesh, Z., Hosseinzadegan, R., Monirvaghefi, K., Pakmehr, S., Pourdeilami, N., Gharedaghi, H., Madani, S. F. S., Azarpey, A., et al. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102291 · Cited by 1
ASIC1a channel in Age-Related Diseases: Therapeutic ImplicationsPreprint
Zhou, R., Liang, H., Hu, W., Ding, J., Li, S., Chen, Y., Zhao, Y., Lü, C., Chen, F., & Hu, W. M. (2022) · doi:10.22541/au.165115867.78502146/v1 · Cited by 1
Alkhazaali-Ali, Z., Negah, S. S., Boroumand, A. R., & Afshari, J. T. (2024) · Preprints.org · doi:10.20944/preprints202404.0366.v1 · Cited by 1
Yousefi, M., Özkan, A., Özmen, K. K., Uysallı, Y., Mamipour, M., Akkaya, N., Amandi, A.-R. D., Atbaşi, A., Heidarzadeh, M., Erdener, Ş. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.17.638582 · Cited by 1
Sehic, F., Voloder, E., Jusufbegović, M., Bulja, D., Konjo, H., Kamenjaković, S., & Vegar-Zubović, S. (2019) · International Journal of Medical Reviews and Case Reports · doi:10.5455/ijmrcr.dir-compared-flair-and-t2w-sequences-evaluation-ms-mri
Interleukin 1 Beta Is Associated With Depression in Multiple Sclerosis PatientsPreprint
Aguilar-Talamantes, H., Islas‐Hernández, A., Rodríguez-Castañeda, A., Bertado-Cortés, B., Corlay-Noriega, I. S. Y., & Garcia-delaTorre, P. (2021) · Research Square · doi:10.21203/rs.3.rs-173017/v1
Immunomodulating, Neuroprotective and Regenerative Modalities in Multiple Sclerosis Management
Chan Mike, K. S., Michele, Z., Tulina, D., Kour Anam, K., Cher, R. L., Moya, R. L., & Fah Michelle, W. B. (2020) · International Journal of Neurodegenerative Disorders · doi:10.23937/2643-4539/1710017
Interleukin 1 beta is associated with depression in Multiple Sclerosis patientsPreprint
Aguilar-Talamantes, H., Islas‐Hernández, A., Rodríguez-Castañeda, A., Bertado-Cortés, B., Corlay-Noriega, I. S. Y., & Garcia-delaTorre, P. (2020) · medRxiv · doi:10.1101/2020.12.11.20245472
Rare co-occurrence of multiple sclerosis and Parkinson's disease: a case report
Ruina, E. A., Alexandrova, E. A., Валерьевна, П. Е., Rodygin, D. N., & Yulin, V. S. (2022) · Annals of Clinical and Experimental Neurology · doi:10.54101/acen.2022.3.10
Halúsková, S., & Vališ, M. (2022) · Neurologie pro praxi · doi:10.36290/neu.2022.041
Epidemiological parameters of multiple sclerosis in Chaharmahal and Bakhtiari Province, Iran
Omrani, M. A., Bayati, A., Sahraian, M. A., & Eskandarieh, S. (2023) · Current Journal of Neurology · doi:10.18502/cjn.v22i2.13337
Prediction of response to disease-modifying therapy in multiple sclerosis
Abdalla, A. M., Nasser, A. A., Fouad, M., & Swelam, M. S. (2023) · Journal of Medicine in Scientific Research · doi:10.59299/2537-0928.1044
Noriega, A. A., Castro-Álvarez, J. F., Berruecos, J. F. Z., Muñoz, N. L., & Vargas, J. A. G. (2024) · Revista Científica de la Sociedad Española de Enfermería Neurológica · doi:10.1016/j.sedene.2024.03.002
Хабиров, Ф. А., Granatov, E. V., Dykhanov, A. Y., & Хайбуллин, Т. И. (2024) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2024-2s-25-30
Anand, M. A. V., Manjula, K. S., & Wang, C. (2024) · Journal of physiological investigation. · doi:10.4103/ejpi.ejpi-d-24-00043 · Cited by 1
Prooxidant-antioxidant balance in relapsing-remitting multiple sclerosis patients
Sabouri, S., Alamdari, D. H., Salaramoli, S., & Hashemy, S. I. (2023) · شهباز. · doi:10.61186/mlj.17.4.20
Acır, İ., Yüksel, B., Soysal, A., & Yayla, V. (2024) · Turkish Journal of Clinics and Laboratory · doi:10.18663/tjcl.1549222
Plasma neurofilament light chain as a biomarker of neuronal damage in multiple sclerosis
Noriega, A. A., Castro-Álvarez, J. F., Berruecos, J. F. Z., Muñoz, N. L., & Vargas, J. A. G. (2024) · Revista Científica de la Sociedad de Enfermería Neurológica (English ed ) · doi:10.1016/j.sedeng.2024.100162
Advances in neurotransmitter detection and modulation: Implications for neurological disorders
Doke, R. R., Bhagwat, A. A., Tambe, P., Vare, P., More, S., Nagare, S., & Shinde, A. (2024) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2024.035
de Almeida, M. M. A., Kornfeld, S. F., Repentigny, Y. D., Al-Aarg, M., Ghani, I., Cummings, S. E., Sutton, E. R., Yaworski, R., McKay, K. S., Gagnon, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5462410/v1
Алексеевна, М. В., Sadovnichuk, E. A., Лепехина, А. С., Бисага, Г. Н., Topuzova, M. P., Shchukina, T. V., Dryagina, N. V., Efimtsev, A. Y., & Alekseeva, T. M. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-025-01762-7
Azarian, A., Jahromi, S. R., Bahramzadeh, K., Saeidi, K., & Kamali, H. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11073-2
Nazari, N., Aligholipour, A., & Sadeghi, M. (2020) · Figshare · doi:10.6084/m9.figshare.13173884
Calpain-2 Regulates Kinesin and Dynein Dysfunction in Neurotoxin-Induced Motoneuron Injury
Zaman, V., Green, C., Sitgreaves, K., Gathings, A., Drasites, K. P., Coleman, N., Huell, J., McDonald, T., Banik, N. L., & Haque, A. (2026) · Brain Sciences · doi:10.3390/brainsci16010092
Kwa, F. A. A., Anjomani‐Virmouni, S., Ramchunder, Z., Kendal, E. S., & Xiao, J. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104644
Rana, M. J., Akand, N., Mamun, M. A., Paul, S., Sharma, P., Noman, A. A., Sharma, H., Narayanan, K., Chitra, Rajendiran, M., et al. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109040
Lazzarotto, A. (2023) · theses.fr (ABES) · doi:10.70675/245e2c82zb2bdz4b9dzbd16zc18dbdc9732b
Neurofilaments: A Promising Diagnostic and Prognostic Biomarker in Multiple Sclerosis
Mathur, D., Mishra, S. V., Rout, S., Kandimalla, R. J. L., Lopez-Iranzo, F. J., López‐Rodas, G., Vinayak, R., Casanova, B., & Mishra, B. K. (2026) · Annals of Neurosciences · doi:10.1177/09727531261421804
Opioid Signaling in Multiple Sclerosis: Emerging Targets for Repair
Perlikowska, R., Domowicz, M., Śliwińska, A., & Stasiołek, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094122
Yaşargün, D. Ö., & Türkoğlu, R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135121
Recent Prospects for the Diagnosis and Management of Multiple Sclerosis: A Succinct Review
Ahmed, R., Al-Jazzar, M. A., & Nasr, M. (2026) · Science and Technology Nexus · doi:10.25259/stn_30_2026
Detection of Lipid-Mediated Diffused Pathological Changes in Multiple SclerosisPreprint
Benyard, B., Kumar, D., Wilson, N. E., Swain, A., Khokhar, S. K., Jacobs, P., Soni, N. D., Schindler, M. K., Haris, M., & Reddy, R. D. (2026) · Research Square · doi:10.21203/rs.3.rs-10730332/v1
Lactate as a metabolic–epigenetic hub in neurological disorders
Gu, Y., Zhang, P., & Lei, C. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01984-9
Nakagawa, Y., & Yamada, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06217-9
DIFFERENCES IN FLOW-MEDIATED DILATATION MEASUREMENTS BETWEEN MULTIPLE SCLEROSIS SUBGROUPS
Alp, Ç., Dogru, M., Alpua, M., & Ulaş, Z. U. (2026) · Kocatepe Tıp Dergisi · doi:10.18229/kocatepetip.1663542
Metadata
- Authors
- Correale, J., Marrodan, M., & Ysrraelit, M. C.
- Affiliations
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (AR)
- Department of Neurology, FLENI, Buenos Aires 1428, Argentina
- Corresponding author
- Correale, Jorge
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2019-02-20
- Volume
- 7
- Issue
- 1
- Pages
- 14
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC6466454
- OpenAlex
- W2917933180
- Cited by
- 167
- References
- 174
- Citations by year
- 2026: 15 · 2025: 25 · 2024: 39 · 2023: 27 · 2022: 20 · 2021: 15 · 2020: 19 · 2019: 7
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Fleni
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Keywords
- multiple sclerosis, progressive multiple sclerosis, neurodegeneration, axonal dysfunction, axonal degeneration, B cell dysregulation, CD8+ T cells, demyelination, microglial activation, reactive oxygen species, mitochondrial damage, calcium accumulation, neuronal loss, disability progression, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review